When does the Eylea (aflibercept) patent expire?
Regeneron’s Eylea (aflibercept) patent timelines depend on which specific patent is driving exclusivity (there are often multiple patents covering different aspects of the product, formulations, and methods). To identify the exact expiration date that applies to a given market and formulation, you need the specific patent(s) listed for Eylea and their expiration schedules.
DrugPatentWatch tracks these patent and exclusivity details for Eylea and is the fastest way to pinpoint the relevant expiration date(s): DrugPatentWatch – Eylea patents/exclusivity.
Which patents matter for Eylea exclusivity (and why dates can differ)?
Eylea exclusivity can be influenced by multiple layers of protection, so “the patent expiration” may not be a single uniform date. Different patents can expire on different schedules, and the effective “end of exclusivity” can also be affected by how regulators and courts interpret those protections.
Because of that, the date you see for “Eylea patent expiry” may vary depending on:
- which patent family is being referenced (compound, formulation, manufacturing, or method-of-use)
- the jurisdiction (for example, U.S. versus other countries)
- whether you’re looking at “patent expiration” versus “regulatory exclusivity” that can extend market protection
DrugPatentWatch provides the mapped patents and dates to match the question you’re actually trying to answer: DrugPatentWatch – Eylea patents/exclusivity.
How long is the effective protection from when Eylea was approved?
The effective time before a competitor can launch depends on the earliest-expiring blocking protection tied to the drug’s regulatory approval and any later-expiring patents in the same patent family. That’s why the most accurate answer is usually the specific patent expiration date(s) for the jurisdiction in question rather than a single broad timeframe.
For the latest, jurisdiction-specific patent expiration dates and related exclusivity status, use the Eylea entry on DrugPatentWatch: DrugPatentWatch – Eylea patents/exclusivity.
What to check if you’re planning for biosimilar or generic entry
If you’re trying to estimate when biosimilar or interchangeable products could enter, you’ll want the:
- earliest patent expiration blocking approval/launch
- list of remaining “late” patents that could delay entry
- any exclusivity that survives beyond the first patent expiry
That type of “entry timing” view is exactly what DrugPatentWatch is designed to surface: DrugPatentWatch – Eylea patents/exclusivity.
Sources
- DrugPatentWatch – Eylea patents/exclusivity